BioCardia, Inc.

Biocardia, Inc.

Biotechnology • Healthcare • Sunnyvale, CA, United States • BCDA (NCM)

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system. BioCardia, Inc. is based in Sunnyvale, California.

650 226 0120 320 Soquel Way, Sunnyvale, CA 94085, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

BioCardia (NASDAQ: BCDA) elects Marvin Slosman to board, honors Dr. Krasno - Stock Titan
Stock Titan • Dec 3
Aug Shorts: What sentiment indicators say about BCDA stock - 2025 Analyst Calls & High Accuracy Investment Signals - moha.gov.vn
moha.gov.vn • Dec 28
BioCardia stock falls after pricing $6 million public offering - Investing.com
Investing.com • Sep 18
Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off - Yahoo Finance
Yahoo Finance • Sep 20
BioCardia Inc. (BCDA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
StocksToTrade • Sep 18

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has BioCardia, Inc. had layoffs?
No layoff events have been recorded for BioCardia, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does BioCardia, Inc. have?
BioCardia, Inc. has approximately 17 employees.
What industry is BioCardia, Inc. in?
BioCardia, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is BioCardia, Inc. a publicly traded company?
Yes, BioCardia, Inc. is publicly traded under the ticker symbol BCDA on the NCM. The company has a market capitalization of approximately $0.01 billion.
Where is BioCardia, Inc. headquartered?
BioCardia, Inc. is headquartered in Sunnyvale, CA, United States at 320 Soquel Way, Sunnyvale, CA 94085, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.